A Phase II Proof-of-Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive In Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib; Ponatinib; Sorafenib; Sunitinib
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Proof of concept; Therapeutic Use
- 20 Sep 2017 Planned End Date changed from 1 Sep 2017 to 30 Mar 2019.
- 20 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Mar 2019.
- 18 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.